Clinical-stage oncology developer creating immuno-oncology and antibody-drug conjugate therapies for cancer, aimed at major unmet patient needs. Uses a proprietary cancer target discovery platform to identify and advance qualified oncology targets, including therapies that both stimulate the immune system and directly attack cancer cells.